person · Reporting owner

MANHARD KIMBERLY

Disclosed activity across 3 companies

Tapewire entity: 41279
SEC CIK: 0001202094

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133	EVP, Drug Development	April 13, 2023	April 17, 2023
Inhibrx Biosciences, Inc.INBX · Entity 4576	Director	June 03, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HERON THERAPEUTICS, INC. /DE/

Report date April 13, 2023 · Filed April 17, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,330	Ending reported balance After 2023-04-13 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2023-04-13 · Exercise / conversion · Acquired 1,250 · Balance 25,183 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2023-04-13 · Exercise / conversion · Acquired 4,564 · Balance 29,747 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 3 · 2023-04-13 · Tax withholding · Disposed 1,417 · Balance 28,330 F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	7,500	Reported balance After 2023-04-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-04-13 · Exercise / conversion · Disposed 1,250 · Balance 7,500 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	27,936	Reported balance After 2023-04-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-04-13 · Exercise / conversion · Disposed 4,564 · Balance 27,936 F1: Restricted stock units convert into common stock on a one-for-one basis. F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Inhibrx Biosciences, Inc.

Report date June 03, 2026 · Filed September 18, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.22 · Expires 2036-06-03	Direct	10,000	Reported balance After 2026-06-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Inhibrx, Inc.

Report date May 30, 2024 · Filed May 30, 2024

Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2030-10-02	Direct	Reported balance After 2024-05-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-30 · Disposition to issuer · Disposed 3,500 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F2: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on October 2, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2033-05-25	Direct	Reported balance After 2024-05-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F4: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2032-05-25	Direct	Reported balance After 2024-05-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.78 · Expires 2031-06-07	Direct	Reported balance After 2024-05-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F6: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.43 · Expires 2030-08-20	Direct	Reported balance After 2024-05-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-30 · Disposition to issuer · Disposed 17,259 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 23, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on October 2, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option.

F4: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F6: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 23, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 15, 2026 Filed Sep 15, 2026 21:52 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	SaleCommon Stock	500	$105.05	$52,525.00	Disclosure SEC source: 0001202094-26-000006 · wk-form4_1789509175.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 Disclosed balance after: 7,500 F1 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Read SEC document
September 14, 2026 Filed Sep 15, 2026 21:52 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	SaleCommon Stock	500	$110.26	$55,130.00	Disclosure SEC source: 0001202094-26-000006 · wk-form4_1789509175.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 Disclosed balance after: 8,000 F1 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Read SEC document
September 11, 2026 Filed Sep 15, 2026 21:52 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	SaleCommon Stock	500	$111.78	$55,887.50	Disclosure SEC source: 0001202094-26-000006 · wk-form4_1789509175.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 Disclosed balance after: 8,500 F1 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Read SEC document
September 09, 2026 Filed Sep 10, 2026 23:06 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	SaleCommon Stock	500	$115.80	$57,897.50	Disclosure SEC source: 0001202094-26-000004 · wk-form4_1789081560.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 Disclosed balance after: 9,000 F1 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Read SEC document
September 08, 2026 Filed Sep 10, 2026 23:06 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	SaleCommon Stock	500	$115.14	$57,570.00	Disclosure SEC source: 0001202094-26-000004 · wk-form4_1789081560.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 Disclosed balance after: 9,500 F1 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Read SEC document
June 03, 2026 Filed Sep 18, 2026 20:22 UTC Amendment	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $95.22	$0.00	Disclosure SEC source: 0001202094-26-000009 · wk-form4a_1789762944.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document
June 03, 2026 Filed Jun 4, 2026 21:28 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $95.22	$0.00	Disclosure SEC source: 0001202094-26-000002 · wk-form4_1780608525.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document
May 28, 2025 Filed May 29, 2025 20:35 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $12.91	$0.00	Disclosure SEC source: 0002007919-25-000072 · wk-form4_1748550943.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-28 F1 · derivative.exercise_date: This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date. Read SEC document
August 28, 2024 Filed Aug 30, 2024 20:16 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	10,000	$13.98	$139,800.00	Disclosure SEC source: 0002007919-24-000042 · wk-form4_1725048989.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 Disclosed balance after: 10,000 F1 · price: The shares were purchased in multiple transactions at prices ranging from $13.925 to $14.04, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	17,259	Not disclosed Strike: $20.43	Not disclosed	Disclosure SEC source: 0000950142-24-001501 · es240484813_4-manhard.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,259 shares Expires 2030-08-20 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F7 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 23, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $24.78	Not disclosed	Disclosure SEC source: 0000950142-24-001501 · es240484813_4-manhard.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-07 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F6 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $12.57	Not disclosed	Disclosure SEC source: 0000950142-24-001501 · es240484813_4-manhard.xml · derivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F5 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $23.03	Not disclosed	Disclosure SEC source: 0000950142-24-001501 · es240484813_4-manhard.xml · derivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F4 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	3,500	Not disclosed Strike: $17.44	Not disclosed	Disclosure SEC source: 0000950142-24-001501 · es240484813_4-manhard.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2030-10-02 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F2 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on October 2, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:11 UTC	Inhibrx Biosciences, Inc. INXB · Entity 4576	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $15.86	$0.00	Disclosure SEC source: 0000950142-24-001494 · es240484864_4-manhard.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-30 F1 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. F2 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. Read SEC document
May 25, 2023 Filed May 30, 2023 20:08 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $23.03	$0.00	Disclosure SEC source: 0001739614-23-000052 · wk-form4_1685477312.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:26 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	4,564	$0.00	$0.00	Disclosure SEC source: 0001209191-23-024497 · doc4.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · EVP, Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,936 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:26 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001209191-23-024497 · doc4.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · EVP, Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:26 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	1,417	$2.88	$4,080.96	Disclosure SEC source: 0001209191-23-024497 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · EVP, Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,330 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:26 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	4,564	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-024497 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · EVP, Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:26 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-024497 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · EVP, Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:08 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantPerformance Stock Units · Derivative	149,365	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-004299 · doc4.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,365 Underlying: Common Stock · 149,365 shares Expires not disclosed F1 · derivative.exercise_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested. F1 · derivative.expiration_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested. Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	4,564	$0.00	$0.00	Disclosure SEC source: 0001209191-23-003560 · doc4.xml · derivative · entry 6 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001209191-23-003560 · doc4.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	2,012	$3.17	$6,378.04	Disclosure SEC source: 0001209191-23-003560 · doc4.xml · nonDerivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,933 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	4,564	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-003560 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-003560 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
October 31, 2022 Filed Jan 17, 2023 22:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	OtherCommon Stock	1,655	$3.27	$5,415.99	Disclosure SEC source: 0001209191-23-003560 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,131 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022. Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	4,564	$0.00	$0.00	Disclosure SEC source: 0001209191-22-053827 · doc4.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,064 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001209191-22-053827 · doc4.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	2,012	$3.76	$7,565.12	Disclosure SEC source: 0001209191-22-053827 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,476 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	4,564	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-053827 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-053827 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 25, 2022 Filed Jul 27, 2022 22:21 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantEmployee Stock Option (Right to Buy) · Derivative	165,961	$0.00 Strike: $3.17	$0.00	Disclosure SEC source: 0001209191-22-043288 · doc4.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,961 Underlying: Common Stock · 165,961 shares Expires 2032-07-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 8 equal quarterly installments beginning one quarter after the date of grant (07/25/2022). Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	4,564	$0.00	$0.00	Disclosure SEC source: 0001209191-22-042259 · doc4.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,628 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001209191-22-042259 · doc4.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	2,012	$3.01	$6,056.12	Disclosure SEC source: 0001209191-22-042259 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,674 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	4,564	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-042259 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:55 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-042259 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
May 25, 2022 Filed May 26, 2022 20:31 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $12.57	$0.00	Disclosure SEC source: 0001739614-22-000061 · wf-form4_165359702607100.xml · derivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,759 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 03, 2022 Filed May 4, 2022 23:01 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	SaleCommon Stock	1,504	$4.76	$7,153.63	Disclosure SEC source: 0001209191-22-027232 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,872 F2 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of September 13, 2021. F3 · price: The range of sales prices received was $4.695 to $4.835. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document
April 29, 2022 Filed May 4, 2022 23:01 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	OtherCommon Stock	1,504	$3.84	$5,778.37	Disclosure SEC source: 0001209191-22-027232 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,376 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022. Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	4,564	$0.00	$0.00	Disclosure SEC source: 0001209191-22-024519 · doc4.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,192 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001209191-22-024519 · doc4.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	2,012	$6.07	$12,212.84	Disclosure SEC source: 0001209191-22-024519 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,872 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	4,564	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-024519 · doc4.xml · nonDerivative · entry 2 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:03 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-024519 · doc4.xml · nonDerivative · entry 1 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:05 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	4,564	$0.00	$0.00	Disclosure SEC source: 0001209191-22-003358 · doc4.xml · derivative · entry 5 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,756 Underlying: Common Stock · 4,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:05 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	1,250	$0.00	$0.00	Disclosure SEC source: 0001209191-22-003358 · doc4.xml · derivative · entry 4 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:05 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	2,012	$8.30	$16,699.60	Disclosure SEC source: 0001209191-22-003358 · doc4.xml · nonDerivative · entry 3 MANHARD KIMBERLY · CIK 0001202094 · Director · EVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,070 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.